| Literature DB >> 29207378 |
Hikmet Akkiz1, Brian I Carr, Kendal Yalçın K, Vito Guerra, Sedef Kuran, Engin Altıntaş, Oğuz Üsküdar, Ümit Karaoğullarından, Ayşegül Özakyol, Salih Tokmak, Mehmet Yücesoy, Halil İbrahim Bahçeci, Abdulalh Ülkü, Tolga Akçam, Kamil Yalçın Polat, Nazım Ekinci, Halis Şimşek, Necati Örmeci, Abdulalh Sonsuz, Mehmet Demir, Murat Kılıç, Ahmet Uygun, Tuğsan Ballı, Ali Demir, Burcu Arslan, Figen Doran.
Abstract
A large cohort of hepatocellular carcinoma (HCC) patients from several collaborating Turkish institutions were examined for the tumor parameters of maximum diameter (MTD), portal vein thrombosis (PVT), and α-fetoprotein (AFP) levels. A relationship was found between MTD and blood platelet levels. Patients with large ≥5 cm tumors who had normal platelet levels had significantly larger tumors, higher percent of PVT, and significantly lower blood total bilirubin and liver cirrhosis than similar ≥5 cm tumor patients having thrombocytopenia. A comparison of patients with and without PVT showed significantly larger tumors, greater multifocality, blood AFP, and C-reactive protein levels, and, interestingly, lower HDL levels in the patients with PVT. Fifty-eight percent of the total cohort had AFP levels ≤100 IU/mL (and 42.1% had values ≤20 IU/mL). These patients had significantly smaller tumors, less tumor multifocality and percent PVT, lower total bilirubin, and less cirrhosis. There was considerable geographic heterogeneity within Turkey in the patterns of HCC presentation, with areas of higher and lower hepatitis B virus, hepatitis D virus, cirrhosis, and tumor aggressiveness parameters. Turkish patients thus have distinct patterns of presentation, but the biological relationships between MTD and both platelets and bilirubin levels are similar to the relationships that have been reported in other ethnic patient groups.Entities:
Keywords: Aggressiveness; Albumin; Hepatocellular carcinoma; Tumor mass; Turkey; α-Fetoprotein
Mesh:
Substances:
Year: 2017 PMID: 29207378 PMCID: PMC5828952 DOI: 10.1159/000484564
Source DB: PubMed Journal: Oncology ISSN: 0030-2414 Impact factor: 2.935